Lucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in study

Lucid Diagnostics (LUCD) announced positive data from a National Cancer Institute-sponsored study demonstrating that its EsoGuard Esophageal DNA Test can effectively detect esophageal precancer among at-risk patients without symptoms of chronic gastroesophageal reflux disease, or GERD, such as heartburn. These results support EsoGuard esophageal precancer testing in an expanded target population. Positive results from this study led to a larger ongoing five-year multicenter clinical study evaluating EsoGuard in asymptomatic patients supported by an $8M National Institutes of Health R01 grant. The study was conducted by investigators at Case Western Reserve University and University Hospitals and enrolled patients without GERD symptoms who otherwise met AGA recommendations for BE screening. EsoGuard demonstrated “excellent” negative predictive value of 100% for detecting esophageal precancer, consistent with its unprecedented precancer detection reported across multiple peer-reviewed clinical validity studies in patients with symptomatic GERD.